Fintel reports that on March 11, 2026, Wolfe Research upgraded their outlook for Vera Therapeutics (NasdaqGM:VERA) from Peer Perform to Outperform.
Analyst Price Forecast Suggests 81.28% Upside
As of February 25, 2026, the average one-year price target for Vera Therapeutics is $76.26/share. The forecasts range from a low of $33.33 to a high of $105.00. The average price target represents an increase of 81.28% from its latest reported closing price of $42.07 / share.
See our leaderboard of companies with the largest price target upside.
The projected annual revenue for Vera Therapeutics is 187MM. The projected annual non-GAAP EPS is -2.80.
What is the Fund Sentiment?
There are 269 funds or institutions reporting positions in Vera Therapeutics. This is an decrease of 84 owner(s) or 23.80% in the last quarter. Average portfolio weight of all funds dedicated to VERA is 0.30%, an increase of 45.80%. Total shares owned by institutions increased in the last three months by 7.21% to 74,440K shares. 
The put/call ratio of VERA is 0.15, indicating a bullish outlook.
What are Other Shareholders Doing?
Avoro Capital Advisors holds 5,889K shares representing 8.25% ownership of the company. In its prior filing, the firm reported owning 6,210K shares , representing a decrease of 5.45%. The firm increased its portfolio allocation in VERA by 25.65% over the last quarter.
Price T Rowe Associates holds 5,462K shares representing 7.65% ownership of the company. In its prior filing, the firm reported owning 3,666K shares , representing an increase of 32.87%. The firm increased its portfolio allocation in VERA by 33.18% over the last quarter.
Deerfield Management Company, L.p. holds 4,060K shares representing 5.69% ownership of the company. In its prior filing, the firm reported owning 3,641K shares , representing an increase of 10.31%. The firm increased its portfolio allocation in VERA by 62.54% over the last quarter.
Kynam Capital Management holds 3,433K shares representing 4.81% ownership of the company. In its prior filing, the firm reported owning 4,028K shares , representing a decrease of 17.32%. The firm increased its portfolio allocation in VERA by 27.43% over the last quarter.
Eversept Partners holds 3,072K shares representing 4.31% ownership of the company. In its prior filing, the firm reported owning 2,808K shares , representing an increase of 8.61%. The firm increased its portfolio allocation in VERA by 39.42% over the last quarter.
Fintel is one of the most comprehensive investing research platforms available to individual investors, traders, financial advisors, and small hedge funds.
Our data covers the world, and includes fundamentals, analyst reports, ownership data and fund sentiment, options sentiment, insider trading, options flow, unusual options trades, and much more. Additionally, our exclusive stock picks are powered by advanced, backtested quantitative models for improved profits.
This story originally appeared on Fintel.
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
